Common cold, also known as nasopharyngitis, is a disease that is caused by viruses and is characterized by coughing, fever, sore throat, and sneezing. Common cold is generally harmless, but due to bacterial infection, it can cause a serious complication, sinuses. Sometimes, it can spread to other body parts and can cause ear infection, throat infection, and pneumonia. People having chronic pulmonary obstructive disease, are more susceptible to common cold. Common cold can spread through direct contact with an infected person such as sneezing, and coughing. Vitamin C is recommended by the medical professionals for the prevention of common cold. Orbis Biosciences, Inc. is in the process of developing ORB-103 for the treatment of common cold. PrEP Biopharm Limited is in the process of developing PrEP-001 as an immunomodulator for the treatment of common cold. Some of the companies having the pipeline of common cold include PrEP Biopharm Limited, Orbis Biosciences, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.